Skip to main content

Atezolizumab / Hyaluronidase Dosage

Medically reviewed by Drugs.com. Last updated on Oct 29, 2024.

Applies to the following strengths: tqjs 1875 mg-30,000 units/15 mL

Usual Adult Dose for Non-Small Cell Lung Cancer

Atezolizumab 1875 mg-hyaluronidase 30,000 units subcutaneously every 3 weeks
Duration of therapy:


Comments:

Use: Non-small cell lung cancer (NSCLC):
expression (PD-L1 stained at least 50% of tumor cells, or PD-L1 stained tumor-infiltrating immune cells covering at least 10% of the tumor area) with no EGFR or ALK genomic tumor aberrations
have had disease progression on an FDA approved therapy for NSCLC while harboring these aberrations prior to receiving this drug.

Usual Adult Dose for Small Cell Lung Cancer

Atezolizumab 1875 mg-hyaluronidase 30,000 units subcutaneously every 3 weeks, in combination with carboplatin and etoposide
Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use: In combination with carboplatin and etoposide, for the first-line treatment of extensive-stage small cell lung cancer

Usual Adult Dose for Hepatocellular Carcinoma

Atezolizumab 1875 mg-hyaluronidase 30,000 units subcutaneously every 3 weeks, in combination with bevacizumab 15 mg/kg IV every 3 weeks
Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use: In combination with bevacizumab, for the treatment of unresectable or metastatic hepatocellular carcinoma not previously treated with systemic therapy

Usual Adult Dose for Melanoma - Metastatic

Atezolizumab 1875 mg-hyaluronidase 30,000 units subcutaneously every 3 weeks, in combination with cobimetinib and vemurafenib
Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use: In combination with cobimetinib and vemurafenib, for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma

Usual Adult Dose for Soft Tissue Sarcoma

Atezolizumab 1875 mg-hyaluronidase 30,000 units subcutaneously every 3 weeks
Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use: As monotherapy, for the treatment of unresectable or metastatic alveolar soft part sarcoma

Renal Dose Adjustments

IMMUNE-MEDIATED NEPHRITIS WITH RENAL DYSFUNCTION:

Liver Dose Adjustments

IMMUNE-MEDIATED HEPATITIS:
Hepatitis With Tumor Involvement of Liver:


Hepatitis WithOUT Tumor Involvement of Liver:

Dose Adjustments

GENERAL CONSIDERATIONS:


IMMUNE MEDIATED ADVERSE REACTIONS:
Colitis:

Endocrinopathies:

Exfoliative Dermatologic Conditions:

Myocarditis or Pericarditis:

Neurological Toxicities:

Pneumonitis:

OTHER ADVERSE REACTIONS:
Infusion-Related Reactions:

Precautions

CONTRAINDICATIONS:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Pretreatment for patients with melanoma: Administer cobimetinib and vemurafenib prior to initiating therapy

Storage requirements:

Reconstitution/preparation techniques:

Compatibility:

General:

Monitoring:
enzymes, creatinine, and thyroid function for early identification of immune reactions (at baseline and periodically during therapy)

Patient advice:

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.